Join this EASL Studio episode for a clinical perspective on advancing HCC care. Explore the realities of adjuvant therapies, emerging molecular targets, and strategies for curative conversion. Gain insights into practical innovations shaping the future and translating research into improved patient outcomes.
Moderator: Thomas Berg Faculty: Tim Greten and Anna Saborowski
This EASL Studio is supported by Bayer. EASL has received no input from Bayer with regards to the content of this programme.
Podden och tillhörande omslagsbild på den här sidan tillhör
European Association for the Study of the Liver. Innehållet i podden är skapat av European Association for the Study of the Liver och inte av,
eller tillsammans med, Poddtoppen.